Compare Abeona Therapeutics Inc (ABEO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while iShares 0 3 Month Treasury Bond ETF trades at $100.51. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | SGOV | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Fixed Income |
52-Week High | $7.45 | $100.74 |
52-Week Low | $4.17 | $100.28 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% with a bearish technical signal from moving averages. It offers a defensive cash alternative, highlighted by recent institutional stake changes and a focus on ultra-short Treasury exposure amid market volatility. The ETF provides monthly distributions, with recent dividends around $0.30 per share.
The outlook remains stable as a low-risk income vehicle, benefiting from rising yields and investor defensive pivots. Key risks include interest rate fluctuations and macroeconomic shifts, but its principal protection and liquidity appeal to cautious investors seeking yield above traditional savings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
